메뉴 건너뛰기




Volumn 19, Issue 7, 2014, Pages 869-881

Antibody-drug conjugates: Current status and future directions

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; ANTIMETABOLITE; BRENTUXIMAB VEDOTIN; CARCINOEMBRYONIC ANTIGEN; CD30 ANTIGEN; CD74 ANTIGEN; CITRULLINE; CYTOTOXIC AGENT; DOXORUBICIN; DRUG ANTIBODY; ENDOTHELIN B RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; FIBRONECTIN; FLUOROURACIL; GEMTUZUMAB OZOGAMICIN; HYDRAZONE DERIVATIVE; INOTUZUMAB OZOGAMICIN; LORVOTUZUMAB MERTANSINE; MALEIMIDE; MAYTANSINE; MILATUZUMAB; MITOMYCIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; TRASTUZUMAB EMTANSINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VINBLASTINE; VINDESINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 84903762549     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.004     Document Type: Review
Times cited : (378)

References (126)
  • 1
    • 73949087586 scopus 로고    scopus 로고
    • Personalized cancer therapy with selective kinase inhibitors: An emerging paradigm in medical oncology
    • U. McDermott, and J. Settleman Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology J. Clin. Oncol. 27 2009 5650 5659
    • (2009) J. Clin. Oncol. , vol.27 , pp. 5650-5659
    • McDermott, U.1    Settleman, J.2
  • 2
    • 0037025173 scopus 로고    scopus 로고
    • Addiction to oncogenes - The Achilles heal of cancer
    • I.B. Weinstein Addiction to oncogenes - the Achilles heal of cancer Science 297 2005 63 64
    • (2005) Science , vol.297 , pp. 63-64
    • Weinstein, I.B.1
  • 3
    • 84871721867 scopus 로고    scopus 로고
    • Overcoming acquired resistance to kinase inhibition: The case of EGFR, ALK, and BRAF
    • S. Giroux Overcoming acquired resistance to kinase inhibition: the case of EGFR, ALK, and BRAF Bioorg. Med. Chem. Lett. 23 2013 394 401
    • (2013) Bioorg. Med. Chem. Lett. , vol.23 , pp. 394-401
    • Giroux, S.1
  • 4
    • 84858005733 scopus 로고    scopus 로고
    • Acquired resistance to drugs targeting receptor tyrosine kinases
    • S.A. Rosenzweig Acquired resistance to drugs targeting receptor tyrosine kinases Biochem. Pharmacol. 83 2012 1041 1048
    • (2012) Biochem. Pharmacol. , vol.83 , pp. 1041-1048
    • Rosenzweig, S.A.1
  • 5
    • 84871698293 scopus 로고    scopus 로고
    • Drug conjugates such as antibody drug conjugates (ADCs), immuotoxins and immunoliposomes challenge daily clinical practice
    • W.-D. Janthur et al. Drug conjugates such as antibody drug conjugates (ADCs), immuotoxins and immunoliposomes challenge daily clinical practice Int. J. Mol. Sci. 13 2012 16020 16045
    • (2012) Int. J. Mol. Sci. , vol.13 , pp. 16020-16045
    • Janthur, W.-D.1
  • 6
    • 80054092984 scopus 로고    scopus 로고
    • Antibody-radionuclide conjugates for cancer therapy: Historical considerations and new trends
    • M. Steiner, and D. Neri Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends Clin. Cancer Res. 17 2011 6406 6416
    • (2011) Clin. Cancer Res. , vol.17 , pp. 6406-6416
    • Steiner, M.1    Neri, D.2
  • 7
    • 0343122931 scopus 로고
    • The relationship existing between chemical constitution, distribution and pharmacological action
    • Wiley & Sons
    • P. Ehrlich The relationship existing between chemical constitution, distribution and pharmacological action Collected Studies on Immunity 1906 Wiley & Sons 441 450
    • (1906) Collected Studies on Immunity , pp. 441-450
    • Ehrlich, P.1
  • 8
    • 84903754700 scopus 로고
    • Chemotherapy. Proceedings of 17th international congress of medicine
    • F. Himmelwiet, Pergamon Press
    • P. Ehrlich Chemotherapy. Proceedings of 17th international congress of medicine F. Himmelwiet, Collected Papers of Paul Ehrlich 1913 Pergamon Press 505 518
    • (1913) Collected Papers of Paul Ehrlich , pp. 505-518
    • Ehrlich, P.1
  • 9
    • 84961023030 scopus 로고
    • Effet sur la leucemie L1210 de la souris d'une combinaison par diazotation d'A-methopterine et de gamma-globulines de hamsters porteur de cette leucemie par heterogreffe
    • G. Mathé et al. Effet sur la leucemie L1210 de la souris d'une combinaison par diazotation d'A-methopterine et de gamma-globulines de hamsters porteur de cette leucemie par heterogreffe C. R. Acad. Sci. 246 1958 1626 1628
    • (1958) C. R. Acad. Sci. , vol.246 , pp. 1626-1628
    • Mathé, G.1
  • 10
    • 0014202195 scopus 로고
    • Immunoradioactive agent against cancer
    • T. Ghose et al. Immunoradioactive agent against cancer Br. Med. J. 1 1967 90 93
    • (1967) Br. Med. J. , vol.1 , pp. 90-93
    • Ghose, T.1
  • 11
    • 0015333917 scopus 로고
    • Antibody as carrier of chlorambucil
    • T. Ghose et al. Antibody as carrier of chlorambucil Cancer 29 1972 1398 1400
    • (1972) Cancer , vol.29 , pp. 1398-1400
    • Ghose, T.1
  • 12
    • 0016831976 scopus 로고
    • Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage
    • G.F. Rowland et al. Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage Nature 255 1975 487 488
    • (1975) Nature , vol.255 , pp. 487-488
    • Rowland, G.F.1
  • 13
    • 0016756272 scopus 로고
    • Continuous cultures of fused cells secreting antibody of predefined specificity
    • G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
    • (1975) Nature , vol.256 , pp. 495-497
    • Kohler, G.1    Milstein, C.2
  • 14
    • 0020674198 scopus 로고
    • Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer
    • C.H.J. Ford et al. Localization and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer Br. J. Cancer 47 1983 35 42 (Pubitemid 13176227)
    • (1983) British Journal of Cancer , vol.47 , Issue.1 , pp. 35-42
    • Ford, C.H.J.1    Newman, C.E.2    Johnson, J.R.3
  • 15
    • 0023911111 scopus 로고
    • Reshaping human antibodies for therapy
    • L. Riechmann et al. Reshaping human antibodies for therapy Nature 332 1988 323 332
    • (1988) Nature , vol.332 , pp. 323-332
    • Riechmann, L.1
  • 16
    • 0028067743 scopus 로고
    • Antibody-targeted drugs for the therapy of cancer
    • G.A. Pietersz, and K. Krauer Antibody-targeted drugs for the therapy of cancer J. Drug Targeting 2 1994 183 215 (Pubitemid 24310624)
    • (1994) Journal of Drug Targeting , vol.2 , Issue.3 , pp. 183-215
    • Pietersz, G.A.1    Krauer, K.2
  • 17
    • 0025854110 scopus 로고
    • The human immune response to KS1/4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies
    • B.H. Petersen et al. The human immune response to KS1/4- desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies Cancer Res. 51 1991 2286 2290
    • (1991) Cancer Res. , vol.51 , pp. 2286-2290
    • Petersen, B.H.1
  • 19
    • 67649886201 scopus 로고    scopus 로고
    • Potent antibody drug conjugates for cancer therapy
    • P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 2009 235 244
    • (2009) Curr. Opin. Chem. Biol. , vol.13 , pp. 235-244
    • Senter, P.D.1
  • 21
    • 0035883042 scopus 로고    scopus 로고
    • Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin
    • M.L. Linenberger et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Blood 98 2001 988 994
    • (2001) Blood , vol.98 , pp. 988-994
    • Linenberger, M.L.1
  • 22
    • 78049515807 scopus 로고    scopus 로고
    • Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
    • A. Younes et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N. Engl. J. Med. 363 2010 1812 1821
    • (2010) N. Engl. J. Med. , vol.363 , pp. 1812-1821
    • Younes, A.1
  • 23
    • 84863688504 scopus 로고    scopus 로고
    • The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    • P. Senter, and E.L. Sievers The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30 2012 631 637
    • (2012) Nat. Biotechnol. , vol.30 , pp. 631-637
    • Senter, P.1    Sievers, E.L.2
  • 24
    • 80054092983 scopus 로고    scopus 로고
    • Trastuzumab emtansine: A unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer
    • P.M. LoRusso et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer Clin. Cancer Res. 17 2011 6437 6447
    • (2011) Clin. Cancer Res. , vol.17 , pp. 6437-6447
    • Lorusso, P.M.1
  • 25
    • 84868520609 scopus 로고    scopus 로고
    • Trastuzumab emtansine for HER2-positive advanced breast cancer
    • S. Verma et al. Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 367 2012 1783 1791
    • (2012) N. Engl. J. Med. , vol.367 , pp. 1783-1791
    • Verma, S.1
  • 26
    • 84877310777 scopus 로고    scopus 로고
    • Maturing antibody-drug conjugate pipeline hits 30
    • A. Mullard Maturing antibody-drug conjugate pipeline hits 30 Nat. Rev. Drug Discov. 12 2013 329 332
    • (2013) Nat. Rev. Drug Discov. , vol.12 , pp. 329-332
    • Mullard, A.1
  • 27
    • 84873053339 scopus 로고    scopus 로고
    • Antibody-drug conjugates in cancer therapy
    • E.L. Sievers, and P.D. Senter Antibody-drug conjugates in cancer therapy Annu. Rev. Med. 64 2013 15 29
    • (2013) Annu. Rev. Med. , vol.64 , pp. 15-29
    • Sievers, E.L.1    Senter, P.D.2
  • 28
    • 84872846418 scopus 로고    scopus 로고
    • Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
    • M. Ritchie et al. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates mAbs 5 2013 13 21
    • (2013) MAbs , vol.5 , pp. 13-21
    • Ritchie, M.1
  • 29
    • 0025359146 scopus 로고
    • Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues
    • M.F. Press et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues Oncogene 5 1990 953 962
    • (1990) Oncogene , vol.5 , pp. 953-962
    • Press, M.F.1
  • 31
    • 33745912498 scopus 로고    scopus 로고
    • Safety of rituximab maintenance therapy in follicular lymphomas
    • P. Solal-Celigny Safety of rituximab maintenance therapy in follicular lymphomas Leuk. Res. 30S1 2006 S16 S21
    • (2006) Leuk. Res. , vol.30 S1
    • Solal-Celigny, P.1
  • 32
    • 9444260479 scopus 로고    scopus 로고
    • Biological impediments to monoclonal antibody-based cancer immunotherapy
    • J. Christiansen, and A.K. Rajasekaran Biological impediments to monoclonal antibody-based cancer immunotherapy Mol. Cancer Ther. 3 2004 1493 1501 (Pubitemid 39562594)
    • (2004) Molecular Cancer Therapeutics , vol.3 , Issue.11 , pp. 1493-1501
    • Christiansen, J.1    Rajasekaran, A.K.2
  • 33
    • 33644787435 scopus 로고    scopus 로고
    • Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen
    • Y.V. Kovtun et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen Cancer Res. 66 2006 3214 3221
    • (2006) Cancer Res. , vol.66 , pp. 3214-3221
    • Kovtun, Y.V.1
  • 34
    • 78650286160 scopus 로고    scopus 로고
    • Investigational antibody-drug conjugates for hematological malignancies
    • A.G. Polson et al. Investigational antibody-drug conjugates for hematological malignancies Expert Opin. Investig. Drugs 20 2011 75 85
    • (2011) Expert Opin. Investig. Drugs , vol.20 , pp. 75-85
    • Polson, A.G.1
  • 35
    • 84877256857 scopus 로고    scopus 로고
    • Insights into antibody-drug conjugates: Bioanalysis and biomeasures in discovery
    • T. Clark et al. Insights into antibody-drug conjugates: bioanalysis and biomeasures in discovery Bioanalysis 5 2013 985 987
    • (2013) Bioanalysis , vol.5 , pp. 985-987
    • Clark, T.1
  • 36
    • 70350494468 scopus 로고    scopus 로고
    • Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma
    • D. Dornan et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma Blood 114 2009 2721 2729
    • (2009) Blood , vol.114 , pp. 2721-2729
    • Dornan, D.1
  • 37
    • 33746095034 scopus 로고    scopus 로고
    • Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/p97
    • DOI 10.1158/1535-7163.MCT-06-0026
    • L.M. Smith et al. Potent cytotoxicity of an auristatin-containing antibody-drug conjugate targeting melanoma cells expressing melanotransferrin/ p97 Mol. Cancer Ther. 5 2006 1474 1482 (Pubitemid 44070484)
    • (2006) Molecular Cancer Therapeutics , vol.5 , Issue.6 , pp. 1474-1482
    • Smith, L.M.1    Nesterova, A.2    Alley, S.C.3    Torgov, M.Y.4    Carter, P.J.5
  • 38
    • 0024509637 scopus 로고
    • Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195
    • M. Tanimoto et al. Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195 Leukemia 3 1989 339 348 (Pubitemid 19127556)
    • (1989) Leukemia , vol.3 , Issue.5 , pp. 339-348
    • Tanimoto, M.1    Scheinberg, D.A.2    Cordon-Cardo, C.3    Huie, D.4    Clarkson, B.D.5    Old, L.J.6
  • 39
    • 84886825064 scopus 로고    scopus 로고
    • SGN-CD33A: A novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML
    • M.S.K. Sutherland et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate utilizing a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML Blood 122 2013 1455 1463
    • (2013) Blood , vol.122 , pp. 1455-1463
    • Sutherland, M.S.K.1
  • 40
    • 80052740269 scopus 로고    scopus 로고
    • In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen
    • X. Wang et al. In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen Mol. Cancer Ther. 10 2011 1728 1739
    • (2011) Mol. Cancer Ther. , vol.10 , pp. 1728-1739
    • Wang, X.1
  • 41
    • 79952256064 scopus 로고    scopus 로고
    • An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma
    • J. Asudi et al. An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma Clin. Cancer Res. 17 2011 965 975
    • (2011) Clin. Cancer Res. , vol.17 , pp. 965-975
    • Asudi, J.1
  • 42
    • 84878263190 scopus 로고    scopus 로고
    • Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody
    • M. Yoshikawa et al. Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody Blood 121 2013 2804 2813
    • (2013) Blood , vol.121 , pp. 2804-2813
    • Yoshikawa, M.1
  • 43
    • 51049105989 scopus 로고    scopus 로고
    • Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
    • M.E. Ackerman et al. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids Mol. Cancer Ther. 7 2008 2233 2240
    • (2008) Mol. Cancer Ther. , vol.7 , pp. 2233-2240
    • Ackerman, M.E.1
  • 44
    • 33646352962 scopus 로고    scopus 로고
    • Potent antibody therapeutics by design
    • P. Carter Potent antibody therapeutics by design Nat. Rev. Immunol. 6 2006 343 357
    • (2006) Nat. Rev. Immunol. , vol.6 , pp. 343-357
    • Carter, P.1
  • 45
    • 84887068994 scopus 로고    scopus 로고
    • Targeting HER21 breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
    • S.C. Owen et al. Targeting HER21 breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles J. Control. Release 172 2013 395 404
    • (2013) J. Control. Release , vol.172 , pp. 395-404
    • Owen, S.C.1
  • 46
    • 33744537358 scopus 로고    scopus 로고
    • Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
    • M.S.K. Sutherland et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates J. Biol. Chem. 281 2006 10540 10547
    • (2006) J. Biol. Chem. , vol.281 , pp. 10540-10547
    • Sutherland, M.S.K.1
  • 47
    • 15244352751 scopus 로고    scopus 로고
    • A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts
    • DOI 10.1021/bc049794n
    • P.R. Hamann et al. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts Bioconjug. Chem. 16 2005 354 360 (Pubitemid 40388211)
    • (2005) Bioconjugate Chemistry , vol.16 , Issue.2 , pp. 354-360
    • Hamann, P.R.1    Hinman, L.M.2    Beyer, C.F.3    Lindh, D.4    Upeslacis, J.5    Shochat, D.6    Mountain, A.7
  • 48
    • 9744243565 scopus 로고    scopus 로고
    • Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
    • C.L. Law et al. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates Clin. Cancer Res. 10 2004 7842 7851
    • (2004) Clin. Cancer Res. , vol.10 , pp. 7842-7851
    • Law, C.L.1
  • 49
    • 52549121490 scopus 로고    scopus 로고
    • Kinetics of anti-carcinoembryonic antigen antibody internalization: Effects of affinity, bivalency, and stability
    • M.M. Schmidt et al. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability Cancer Immunol. Immunother. 57 2008 1879 1890
    • (2008) Cancer Immunol. Immunother. , vol.57 , pp. 1879-1890
    • Schmidt, M.M.1
  • 50
    • 0037931402 scopus 로고    scopus 로고
    • Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis. Distribution of homo- and heterodimers depends on relative HER2 levels
    • DOI 10.1074/jbc.M300477200
    • B.S. Hendriks et al. Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels J. Biol. Chem. 278 2003 23343 23351 (Pubitemid 36830149)
    • (2003) Journal of Biological Chemistry , vol.278 , Issue.26 , pp. 23343-23351
    • Hendriks, B.S.1    Opresko, L.K.2    Wiley, H.S.3    Lauffenburger, D.4
  • 51
    • 0029820796 scopus 로고    scopus 로고
    • Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas
    • H.J. Hansen et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas Biochem. J. 320 1996 293 300
    • (1996) Biochem. J. , vol.320 , pp. 293-300
    • Hansen, H.J.1
  • 53
    • 20344367537 scopus 로고    scopus 로고
    • Tumour vascular targeting
    • DOI 10.1038/nrc1627
    • D. Neri, and R. Bicknell Tumour vascular targeting Nat. Rev. Cancer 5 2005 436 446 (Pubitemid 40791486)
    • (2005) Nature Reviews Cancer , vol.5 , Issue.6 , pp. 436-446
    • Neri, D.1    Bicknell, R.2
  • 54
    • 79953185350 scopus 로고    scopus 로고
    • A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
    • A. Palumbo et al. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels Br. J. Cancer 104 2011 1106 1115
    • (2011) Br. J. Cancer , vol.104 , pp. 1106-1115
    • Palumbo, A.1
  • 55
    • 54049093284 scopus 로고    scopus 로고
    • Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
    • C.F. McDonagh et al. Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index Mol. Cancer Ther. 7 2008 2913 2923
    • (2008) Mol. Cancer Ther. , vol.7 , pp. 2913-2923
    • McDonagh, C.F.1
  • 56
    • 79959700509 scopus 로고    scopus 로고
    • Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
    • T.T. Junttila et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer Breast Cancer Res. Treat. 128 2011 347 356
    • (2011) Breast Cancer Res. Treat. , vol.128 , pp. 347-356
    • Junttila, T.T.1
  • 58
    • 31544455876 scopus 로고    scopus 로고
    • Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma
    • J.F. DiJoseph et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma Clin. Cancer Res. 12 2006 242 249
    • (2006) Clin. Cancer Res. , vol.12 , pp. 242-249
    • Dijoseph, J.F.1
  • 59
    • 79952660539 scopus 로고    scopus 로고
    • Antibody-drug conjugates: Using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells
    • V.S. Goldmacher, and Y.V. Kovtun Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells Ther. Deliv. 2 2011 397 416
    • (2011) Ther. Deliv. , vol.2 , pp. 397-416
    • Goldmacher, V.S.1    Kovtun, Y.V.2
  • 60
    • 48649094750 scopus 로고    scopus 로고
    • Fully human antibodies from transgenic mouse and phage display platforms
    • N. Lonberg Fully human antibodies from transgenic mouse and phage display platforms Curr. Opin. Immunol. 20 2008 450 459
    • (2008) Curr. Opin. Immunol. , vol.20 , pp. 450-459
    • Lonberg, N.1
  • 62
    • 0032402354 scopus 로고    scopus 로고
    • Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin
    • PII S0960894X9800609X
    • G.M. Dubowchik, and R.A. Firestone Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 8 1998 3341 3346 (Pubitemid 28547069)
    • (1998) Bioorganic and Medicinal Chemistry Letters , vol.8 , Issue.23 , pp. 3341-3346
    • Dubowchik, G.M.1    Firestone, R.A.2
  • 63
    • 0036074253 scopus 로고    scopus 로고
    • Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
    • DOI 10.1021/bc025536j
    • G.M. Dubowchik et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity Bioconjug. Chem. 13 2002 855 869 (Pubitemid 34801129)
    • (2002) Bioconjugate Chemistry , vol.13 , Issue.4 , pp. 855-869
    • Dubowchik, G.M.1    Firestone, R.A.2    Padilla, L.3    Willner, D.4    Hofstead, S.J.5    Mosure, K.6    Knipe, J.O.7    Lasch, S.J.8    Trail, P.A.9
  • 65
    • 74949107560 scopus 로고    scopus 로고
    • Antibody-drug conjugates: Linking cytotoxic payloads to monoclonal antibodies
    • L. Ducry, and B. Stump Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies Bioconjug. Chem. 21 2010 5 13
    • (2010) Bioconjug. Chem. , vol.21 , pp. 5-13
    • Ducry, L.1    Stump, B.2
  • 67
    • 79960356302 scopus 로고    scopus 로고
    • Investigational antibody drug conjugates for solid tumors
    • P. Sapra et al. Investigational antibody drug conjugates for solid tumors Expert Opin. Investig. Drugs 20 2011 1131 1149
    • (2011) Expert Opin. Investig. Drugs , vol.20 , pp. 1131-1149
    • Sapra, P.1
  • 68
    • 0347926091 scopus 로고    scopus 로고
    • Drug delivery strategy utilizing conjugation via reversible disulfide linkages: Role and site of cellular reducing activities
    • G. Sato et al. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities Adv. Drug Deliv. Rev. 55 2003 199 215
    • (2003) Adv. Drug Deliv. Rev. , vol.55 , pp. 199-215
    • Sato, G.1
  • 69
    • 74949139946 scopus 로고    scopus 로고
    • Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates
    • H.K. Erickson Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates Bioconjug. Chem. 21 2010 84 92
    • (2010) Bioconjug. Chem. , vol.21 , pp. 84-92
    • Erickson, H.K.1
  • 70
    • 84903791373 scopus 로고    scopus 로고
    • Inc. Protein-polymer-drug conjugates. U.S. Patent Appl. 20130101546
    • Yurkovetskiy, A.V. Mersana Therapeutics, Inc. Protein-polymer-drug conjugates. U.S. Patent Appl. 20130101546.
    • Mersana Therapeutics
    • Yurkovetskiy, A.V.1
  • 72
    • 78650532605 scopus 로고    scopus 로고
    • The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity
    • K.M. Bajjuri et al. The legumain protease-activated auristatin prodrugs suppress tumor growth and metastasis without toxicity ChemMedChem 6 2011 54 59
    • (2011) ChemMedChem , vol.6 , pp. 54-59
    • Bajjuri, K.M.1
  • 73
    • 77956498321 scopus 로고    scopus 로고
    • Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents
    • S.C. Jeffrey et al. Expanded utility of the β-glucuronide linker: ADCs that deliver phenolic cytotoxic agents ACS Med. Chem. Lett. 1 2010 277 280
    • (2010) ACS Med. Chem. Lett. , vol.1 , pp. 277-280
    • Jeffrey, S.C.1
  • 74
    • 84868560034 scopus 로고    scopus 로고
    • The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy
    • T. Legigan et al. The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy Angew. Chem. Int. Ed. 51 2012 11606 11610
    • (2012) Angew. Chem. Int. Ed. , vol.51 , pp. 11606-11610
    • Legigan, T.1
  • 75
    • 0026593928 scopus 로고
    • Immunoconjugates containing novel maytansinoids: Promising anticancer drugs
    • R.V. Chari et al. Immunoconjugates containing novel maytansinoids: promising anticancer drugs Cancer Res. 52 1992 127 131
    • (1992) Cancer Res. , vol.52 , pp. 127-131
    • Chari, R.V.1
  • 76
    • 0027194197 scopus 로고
    • Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics
    • L.M. Hinmann et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics Cancer Res. 53 1993 3336 3342
    • (1993) Cancer Res. , vol.53 , pp. 3336-3342
    • Hinmann, L.M.1
  • 80
    • 80054098573 scopus 로고    scopus 로고
    • Antibody conjugate therapeutics: Challenges and potential
    • B.A. Teicher, and R.V.J. Chari Antibody conjugate therapeutics: challenges and potential Clin. Cancer Res. 17 2011 6389 6397
    • (2011) Clin. Cancer Res. , vol.17 , pp. 6389-6397
    • Teicher, B.A.1    Chari, R.V.J.2
  • 81
    • 79955867207 scopus 로고    scopus 로고
    • The development of pyrrolobenzodiazepines as antitumor agents
    • J.A. Hartley The development of pyrrolobenzodiazepines as antitumor agents Expert Opin. Investig. Drugs 20 2011 733 744
    • (2011) Expert Opin. Investig. Drugs , vol.20 , pp. 733-744
    • Hartley, J.A.1
  • 82
    • 84860142832 scopus 로고    scopus 로고
    • Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma
    • G. Moldenhauer et al. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma J. Natl. Cancer Inst. 104 2012 1 13
    • (2012) J. Natl. Cancer Inst. , vol.104 , pp. 1-13
    • Moldenhauer, G.1
  • 87
    • 0033852105 scopus 로고    scopus 로고
    • Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines
    • K. Naito et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines Leukemia 14 2000 1436 1443 (Pubitemid 30601355)
    • (2000) Leukemia , vol.14 , Issue.8 , pp. 1436-1443
    • Naito, K.1    Takeshita, A.2    Shigeno, K.3    Nakamura, S.4    Fujisawa, S.5    Shinjo, K.6    Yoshida, H.7    Ohnishi, K.8    Mori, M.9    Terakawa, S.10    Ohno, R.11
  • 88
    • 0043240102 scopus 로고    scopus 로고
    • Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells
    • DOI 10.1182/blood-2003-02-0396
    • R.B. Walter et al. Multidrug resistance protein attenuates gemtuzumab ozogamicin-induced cytotoxicity in acute myeloid leukemia cells Blood 102 2003 1466 1473 (Pubitemid 36988058)
    • (2003) Blood , vol.102 , Issue.4 , pp. 1466-1473
    • Walter, R.B.1    Raden, B.W.2    Hong, T.C.3    Flowers, D.A.4    Bernstein, I.D.5    Linenberger, M.L.6
  • 89
    • 13544266555 scopus 로고    scopus 로고
    • CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance
    • DOI 10.1038/sj.leu.2403598
    • M.L. Linenberger CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance Leukemia 19 2005 176 182 (Pubitemid 40220577)
    • (2005) Leukemia , vol.19 , Issue.2 , pp. 176-182
    • Linenberger, M.L.1
  • 90
    • 67650733509 scopus 로고    scopus 로고
    • P-gP activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute leukaemia patients
    • R. Tang et al. P-gP activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute leukaemia patients BMC Cancer 9 2009 1 10
    • (2009) BMC Cancer , vol.9 , pp. 1-10
    • Tang, R.1
  • 92
    • 49449087300 scopus 로고    scopus 로고
    • Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
    • J.R. Junutula et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index Nat. Biotechnol. 26 2008 925 932
    • (2008) Nat. Biotechnol. , vol.26 , pp. 925-932
    • Junutula, J.R.1
  • 93
    • 84879376486 scopus 로고    scopus 로고
    • Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates
    • N.J. Boylan et al. Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates Bioconjug. Chem. 24 2013 1008 1016
    • (2013) Bioconjug. Chem. , vol.24 , pp. 1008-1016
    • Boylan, N.J.1
  • 94
    • 84871368732 scopus 로고    scopus 로고
    • Considerations for the safe and effective manufacturing of antibody drug conjugates
    • T. Rohrer Considerations for the safe and effective manufacturing of antibody drug conjugates Chem. Oggi/Chem. Today 30 2012 76 79
    • (2012) Chem. Oggi/Chem. Today , vol.30 , pp. 76-79
    • Rohrer, T.1
  • 96
    • 0034730518 scopus 로고    scopus 로고
    • Site-specific conjugation on serine → cysteine variant monoclonal antibodies
    • J.B. Stimmel et al. Site-specific conjugation on serine → cysteine variant monoclonal antibodies J. Biol. Chem. 39 2000 30445 30450
    • (2000) J. Biol. Chem. , vol.39 , pp. 30445-30450
    • Stimmel, J.B.1
  • 97
    • 40649126110 scopus 로고    scopus 로고
    • Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs
    • J.R. Junutula et al. Rapid identification of reactive cysteine residues for site-specific labeling of antibody-Fabs J. Immunol. Methods 332 2008 41 52
    • (2008) J. Immunol. Methods , vol.332 , pp. 41-52
    • Junutula, J.R.1
  • 99
    • 84867040452 scopus 로고    scopus 로고
    • Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
    • J.Y. Axup et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids Proc. Natl. Acad. Sci. U. S. A. 109 2012 16101 16106
    • (2012) Proc. Natl. Acad. Sci. U. S. A. , vol.109 , pp. 16101-16106
    • Axup, J.Y.1
  • 100
    • 77951236321 scopus 로고    scopus 로고
    • Beyond the canonical 20 amino acids: Expanding the genetic lexicon
    • T.S. Young, and P.G. Schultz Beyond the canonical 20 amino acids: expanding the genetic lexicon J. Biol. Chem. 285 2010 11039 11044
    • (2010) J. Biol. Chem. , vol.285 , pp. 11039-11044
    • Young, T.S.1    Schultz, P.G.2
  • 101
    • 84863249248 scopus 로고    scopus 로고
    • Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system
    • G. Yin et al. Aglycosylated antibodies and antibody fragments produced in a scalable in vitro transcription-translation system mAbs 4 2012 217 225
    • (2012) MAbs , vol.4 , pp. 217-225
    • Yin, G.1
  • 102
    • 34249076359 scopus 로고    scopus 로고
    • Introducing genetically encoded aldehydes into proteins
    • DOI 10.1038/nchembio878, PII NCHEMBIO878
    • I.S. Carrico et al. Introducing genetically encoded aldehydes into proteins Nat. Chem. Biol. 3 2007 321 322 (Pubitemid 46789266)
    • (2007) Nature Chemical Biology , vol.3 , Issue.6 , pp. 321-322
    • Carrico, I.S.1    Carlson, B.L.2    Bertozzi, C.R.3
  • 103
    • 84861034877 scopus 로고    scopus 로고
    • Site-specific chemical protein conjugation using genetically encoded aldehyde tags
    • D. Rabuka et al. Site-specific chemical protein conjugation using genetically encoded aldehyde tags Nat. Protoc. 7 2012 1052 1067
    • (2012) Nat. Protoc. , vol.7 , pp. 1052-1067
    • Rabuka, D.1
  • 104
    • 84871947711 scopus 로고    scopus 로고
    • A Pictet-Spengler ligation for protein chemical modification
    • P. Agarwal et al. A Pictet-Spengler ligation for protein chemical modification Proc. Natl. Acad. Sci. U. S. A. 110 2013 46 51
    • (2013) Proc. Natl. Acad. Sci. U. S. A. , vol.110 , pp. 46-51
    • Agarwal, P.1
  • 105
    • 70349266046 scopus 로고    scopus 로고
    • Site specific protein labeling by enzymatic posttranslational modification
    • M. Sunbul, and J. Yin Site specific protein labeling by enzymatic posttranslational modification Org. Biomol. Chem. 7 2009 3361 3371
    • (2009) Org. Biomol. Chem. , vol.7 , pp. 3361-3371
    • Sunbul, M.1    Yin, J.2
  • 106
    • 78650297318 scopus 로고    scopus 로고
    • Site-specific and stiochiometric modification of antibodies by bacterial transglutaminase
    • S. Jeger et al. Site-specific and stiochiometric modification of antibodies by bacterial transglutaminase Angew. Chem. Int. Ed. 49 2010 9995 9997
    • (2010) Angew. Chem. Int. Ed. , vol.49 , pp. 9995-9997
    • Jeger, S.1
  • 107
    • 84874300889 scopus 로고    scopus 로고
    • Location matters: Site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates
    • P. Strop et al. Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates Chem. Biol. 20 2013 161 167
    • (2013) Chem. Biol. , vol.20 , pp. 161-167
    • Strop, P.1
  • 108
    • 84859891859 scopus 로고    scopus 로고
    • Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation
    • N.P. Madej et al. Engineering of an anti-epidermal growth factor receptor antibody to single chain format and labeling by sortase A-mediated protein ligation Biotechol. Bioeng. 109 2012 1461 1470
    • (2012) Biotechol. Bioeng. , vol.109 , pp. 1461-1470
    • Madej, N.P.1
  • 109
    • 84874343465 scopus 로고    scopus 로고
    • Drug-conjugated antibodies for the treatment of cancer
    • J.M. Lambert Drug-conjugated antibodies for the treatment of cancer Br. J. Clin. Pharmacol. 76 2012 248 262
    • (2012) Br. J. Clin. Pharmacol. , vol.76 , pp. 248-262
    • Lambert, J.M.1
  • 110
    • 84860121680 scopus 로고    scopus 로고
    • The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: Results of the UK NCRI AML16 randomized trial
    • A.K. Burnett et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial Blood 118 2011 582
    • (2011) Blood , vol.118 , pp. 582
    • Burnett, A.K.1
  • 111
    • 0033052777 scopus 로고    scopus 로고
    • Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death
    • C. Dumontet, and B.I. Sikic Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death J. Clin. Oncol. 17 1999 1061 1070 (Pubitemid 29109340)
    • (1999) Journal of Clinical Oncology , vol.17 , Issue.3 , pp. 1061-1070
    • Dumontet, C.1    Sikic, B.I.2
  • 112
    • 84864544136 scopus 로고    scopus 로고
    • Phase i multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma
    • A. Younes et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma J. Clin. Oncol. 30 2012 2776 2782
    • (2012) J. Clin. Oncol. , vol.30 , pp. 2776-2782
    • Younes, A.1
  • 114
    • 79960248682 scopus 로고    scopus 로고
    • Phase i study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma - A preliminary safety and efficacy analysis of the combination
    • J.G. Berdeja et al. Phase I study of lorvotuzumab mertansine (IMGN901) in combination with lenalidomide and dexamethasone in patients with CD56-positive relapsed or relapsed/refractory multiple myeloma - a preliminary safety and efficacy analysis of the combination Blood 116 2010 1934
    • (2010) Blood , vol.116 , pp. 1934
    • Berdeja, J.G.1
  • 117
    • 84866735537 scopus 로고    scopus 로고
    • Pharmacokinetic considerations for antibody drug conjugates
    • K. Lin, and J. Tibbitts Pharmacokinetic considerations for antibody drug conjugates Pharm. Res. 29 2012 2354 2366
    • (2012) Pharm. Res. , vol.29 , pp. 2354-2366
    • Lin, K.1    Tibbitts, J.2
  • 118
    • 84877285215 scopus 로고    scopus 로고
    • Strategies to address drug interaction potential for antibody-drug conjugates in clinical development
    • D. Lu et al. Strategies to address drug interaction potential for antibody-drug conjugates in clinical development Bioanalysis 5 2013 1115 1130
    • (2013) Bioanalysis , vol.5 , pp. 1115-1130
    • Lu, D.1
  • 119
  • 120
    • 84903781978 scopus 로고    scopus 로고
    • Multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): An antibody-drug conjugate for the treatment of HER2-positive cancer [abstract]
    • B. Bender et al. Multicompartmental population PK model elucidating the complex disposition of trastuzumab emtansine (T-DM1): an antibody-drug conjugate for the treatment of HER2-positive cancer [abstract] Abstracts of the Annual Meeting Population Approach Group in Europe. Abstract nr 2607, PAGE 2012 21
    • (2012) Abstracts of the Annual Meeting Population Approach Group in Europe. Abstract Nr 2607, PAGE , pp. 21
    • Bender, B.1
  • 121
    • 84862752215 scopus 로고    scopus 로고
    • The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates
    • H.K. Erikson et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates Mol. Cancer Ther. 11 2012 1133 1142
    • (2012) Mol. Cancer Ther. , vol.11 , pp. 1133-1142
    • Erikson, H.K.1
  • 122
    • 34548229364 scopus 로고    scopus 로고
    • FcRn: The neonatal Fc receptor comes of age
    • DOI 10.1038/nri2155, PII NRI2155
    • D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev. Immunol. 7 2007 715 725 (Pubitemid 47327396)
    • (2007) Nature Reviews Immunology , vol.7 , Issue.9 , pp. 715-725
    • Roopenian, D.C.1    Akilesh, S.2
  • 123
    • 84879591299 scopus 로고    scopus 로고
    • The antibody-drug conjugate: An enabling modality for natural-product based cancer therapeutics
    • H.-P. Gerber et al. The antibody-drug conjugate: an enabling modality for natural-product based cancer therapeutics Nat. Prod. Res. 2013 625 639
    • (2013) Nat. Prod. Res. , pp. 625-639
    • Gerber, H.-P.1
  • 124
    • 84874117009 scopus 로고    scopus 로고
    • Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake
    • B. Gorovits, and C. Krinos-Fiorotti Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake Cancer Immunol. Immunother. 62 2013 217 223
    • (2013) Cancer Immunol. Immunother. , vol.62 , pp. 217-223
    • Gorovits, B.1    Krinos-Fiorotti, C.2
  • 125
    • 49449119098 scopus 로고    scopus 로고
    • Antibody-drug conjugates for cancer therapy
    • P. Carter, and P. Senter Antibody-drug conjugates for cancer therapy Cancer J. 14 2008 154 168
    • (2008) Cancer J. , vol.14 , pp. 154-168
    • Carter, P.1    Senter, P.2
  • 126
    • 84863012529 scopus 로고    scopus 로고
    • Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
    • B.-Q. Shen et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30 2012 184 189
    • (2012) Nat. Biotechnol. , vol.30 , pp. 184-189
    • Shen, B.-Q.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.